UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas

Nature reviews. Clinical oncology, 2017-04, Vol.14 (4), p.203-220

2017

Volltextzugriff (PDF)

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

Molecular cancer therapeutics, 2017-11, Vol.16 (11), p.2598-2608

2017

Volltextzugriff (PDF)

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

Molecular cancer therapeutics, 2015-04, Vol.14 (4), p.847-856

2015

Volltextzugriff (PDF)

Impact of Sotorasib and Adagrasib in KRAS G12C--Mutated NSCLC

Oncology (Williston Park, N.Y.), 2023-12, Vol.37 (12), p.479

Patel, Sandip P

2023

Volltextzugriff (PDF)

Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients

Clinical cancer research, 2016-11, Vol.22 (22), p.5497-5505

2016

Volltextzugriff (PDF)

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors

Clinical cancer research, 2020-05, Vol.26 (10), p.2290-2296

2020

Volltextzugriff (PDF)

Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy

Clinical cancer research, 2017-10, Vol.23 (19), p.5729-5736

2017

Volltextzugriff (PDF)

Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers: A Systematic Review and Meta-analysis

JAMA oncology, 2019-04, Vol.5 (4), p.529

2019

Volltextzugriff (PDF)

Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer

JAMA oncology, 2020-12, Vol.6 (12), p.1952

2020

Volltextzugriff (PDF)

Immune-Related Toxicity in NSCLC: Current State-of-the-Art and Emerging Clinical Challenges

Journal of thoracic oncology, 2024-03, Vol.19 (3), p.395-408

2024

Volltextzugriff (PDF)

Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trial

JNCI : Journal of the National Cancer Institute, 2024-05, Vol.116 (5), p.673-680

2024

Volltextzugriff (PDF)

Disparities in telemedicine during COVID‐19

Cancer medicine (Malden, MA), 2022-02, Vol.11 (4), p.1192-1201

2022

Volltextzugriff (PDF)

Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma

Clinical cancer research, 2017-09, Vol.23 (17), p.5101-5111

2017

Volltextzugriff (PDF)

Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Response

Clinical cancer research, 2020-05, Vol.26 (10), p.2434-2434

2020

Volltextzugriff (PDF)

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

Journal for immunotherapy of cancer, 2021-08, Vol.9 (8), p.e002990

2021

Volltextzugriff (PDF)

Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining "Actionability" of a Molecular Lesion and Patient Management Support

Molecular cancer therapeutics, 2017-12, Vol.16 (12), p.2645-2655

2017

Volltextzugriff (PDF)

Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications

BMC cancer, 2020-05, Vol.20 (1), p.383-13, Article 383

2020

Volltextzugriff (PDF)

Association between PD-L1 status and immune checkpoint inhibitor response in advanced malignancies: a systematic review and meta-analysis of overall survival data

Japanese journal of clinical oncology, 2020-07, Vol.50 (7), p.800-809

2020

Volltextzugriff (PDF)

First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20 + Non-Hodgkin Lymphomas

Clinical cancer research, 2020-06, Vol.26 (11), p.2524-2534

2020

Volltextzugriff (PDF)

Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients

Molecular oncology, 2021-01, Vol.15 (1), p.67-79

2021

Volltextzugriff (PDF)

Disparities and trends in the participation of minorities, women, and the elderly in breast, colorectal, lung, and prostate cancer clinical trials

Cancer, 2022-02, Vol.128 (4), p.770-777

2022

Volltextzugriff (PDF)

Landscape of Immune-Related Pneumonitis in Cancer Patients with Asthma Being Treated with Immune Checkpoint Blockade

Oncology, 2020-02, Vol.98 (2), p.123-130

2020

Volltextzugriff (PDF)

Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort

Cancer Immunology, Immunotherapy, 2020-07, Vol.69 (7), p.1177-1187

2020

Volltextzugriff (PDF)

Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival

Cancer Immunology, Immunotherapy, 2022-05, Vol.71 (5), p.1157-1165

2022

Volltextzugriff (PDF)

Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer

Cancer Immunology, Immunotherapy, 2023-02, Vol.72 (2), p.339-350

2023

Volltextzugriff (PDF)

1 – 25 von 135

Suche als RSS-Feed

Aktive Filter

ThemaOncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(118)
Mit Volltextzugriff
(119)

Publikationsform

Artikel
(122)
Buchkapitel
(13)

Sprache

Englisch
(135)
Japanisch
(11)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

Impact of Sotorasib and Adagrasib in KRAS G12C--Mutated NSCLC

Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors

Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy

Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers: A Systematic Review and Meta-analysis

Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer

Immune-Related Toxicity in NSCLC: Current State-of-the-Art and Emerging Clinical Challenges

Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trial

Disparities in telemedicine during COVID‐19

Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma

Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Response

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining "Actionability" of a Molecular Lesion and Patient Management Support

Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications

Association between PD-L1 status and immune checkpoint inhibitor response in advanced malignancies: a systematic review and meta-analysis of overall survival data

First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20 + Non-Hodgkin Lymphomas

Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients

Disparities and trends in the participation of minorities, women, and the elderly in breast, colorectal, lung, and prostate cancer clinical trials

Landscape of Immune-Related Pneumonitis in Cancer Patients with Asthma Being Treated with Immune Checkpoint Blockade

Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort

Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival

Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer

Aktive Filter

Suchergebnisse filtern